FDA Approves Glofitamab (Columvi) for DLBCL : vimarsana.com

The drug is a T-cell-engaging bispecific antibody and has been approved for use in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Related Keywords

Siteman Cancer Center , Missouri , United States , Sweden , Washington University , Swedish , Nancy Bartlett , Krish Patel , Lymphoma Program , Drug Administration , Genentech , Washington University School Of Medicine , Swedish Cancer Institute In Seattle , New England Journal , Washington University School , Common Form , Swedish Cancer Institute ,